Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor

✍ Scribed by Renato G. S. Chirvi; Angela Garofalo; Michael J. Crimmin; Lindsay J. Bawden; Antonella Stoppacciaro; Peter D. Brown; Raffaella Giavazzi

• Publisher: John Wiley and Sons
• Year: 1994
• Tongue: French
• Weight: 675 KB
• Volume: 58
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910580326

✦ Synopsis

The synthetic matrix metalloproteinase inhibitor batimastat was tested for its ability to inhibit growth and metastatic spread of the B16-BL6 murine melanoma in syngeneic C57BL/6N mice. lntraperitoneal administration of batimastat resulted in a significant inhibition in the number of lung colonies produced by B I b B L 6 cells injected i.v. The effect of batimastat on spontaneous metastases was examined in mice inoculated in the hind footpad with B16-BL6 melanoma. The primary tumor was removed surgically after 26-28 days. Batimastat was administered twice a day from day 14 to day 28 (pre-surgery) or from day 26 to day 44 (post-surgery). With both protocols, the median number of lung metastases was not significantly affected, but there was a significant reduction in the weight of the metastases. Finally, the effect of batimastat was examined on S.C. growth of B l b B L 6 melanoma. Batimastat administered daily, starting at day of tumor transplantation, resulted in a significant growth delay, whereas treatment starting at advanced stage tumor only reduced tumor growth marginally. Our results indicate that a matrix metalloproteinase inhibitor can not only prevent the colonization of secondary organs by B l b B L 6 cells but also limit the growth of solid tumors.